The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Large drug trials have become very important to determine which drugs should be used in the treatment of patients with chronic heart failure (CHF). When these trials showed "positive" results, publication of the data soon followed, leading to a substantial impact on prescription patterns. In the case of "negative" results, many times they were not published, or were reported as an abstract or as short paper disclosing only the main findings. In this article we will discuss some of these trials that were conducted in the last 10 years, since we believe they may provide insight into the pathophysiology and treatment options in CHF.
van Veldhuisen
D J
DJ
Department of Cardiology/Thoraxcentre, University Hospital Groningen, P.O. Box 30001, 9700 RB, Groningen, The Netherlands. d.j.van.veldhuisen@thorax.azg.nl
Poole-Wilson
P A
PA
D000077300:Bosentan; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003846:Deoxyepinephrine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D020748:Mibefradil / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D017307:Xamoterol / Q000494:pharmacology / Q000627:therapeutic use
D002317:Cardiovascular Agents; D007093:Imidazoles; D011719:Pyrazines; D011804:Quinolines; D013449:Sulfonamides; D020748:Mibefradil; C041667:vesnarinone; C047316:flosequinan; D017307:Xamoterol; C023487:ibopamine; C043482:moxonidine; D000077300:Bosentan; D003846:Deoxyepinephrine